Common side effects
The tablet trial found a familiar semaglutide side-effect pattern—but route-specific evidence matters
The current DailyMed label describes a placebo-controlled trial of once-daily Wegovy 25 mg tablets in adults with obesity or overweight and at least one weight-related condition. The label says the types and frequency of common adverse reactions were similar to those in its main Wegovy adverse-reaction table. That table includes nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, indigestion, dizziness, abdominal distension, burping, low blood sugar in people with type 2 diabetes, gas, gastroenteritis, reflux, and gastritis. The oral study excluded people with type 2 diabetes, and percentages from injection studies should not be copied as exact tablet risks or a personal forecast.
- In the tablet trial, 6.9% of Wegovy-treated participants and 5.9% of placebo participants permanently discontinued because of adverse reactions.
- Gastrointestinal reactions were the most common event type leading to discontinuation: 3.4% with Wegovy tablets and 2% with placebo.
- Persistent symptoms, reduced intake, or trouble following the tablet routine should be reviewed by the prescriber rather than managed with a social-media dose hack.
Abdominal and hydration risks
Severe pain, repeated vomiting, dehydration, or gallbladder symptoms need escalation
The Wegovy label includes warnings for acute pancreatitis, acute gallbladder disease, acute kidney injury due to volume depletion, and severe gastrointestinal reactions. Repeated vomiting or diarrhea can cause dehydration and may worsen kidney function, particularly during initiation or escalation or in someone with kidney disease, diuretics, or other medicines that affect fluid balance. Severe or persistent abdominal pain—sometimes radiating to the back—with or without vomiting may signal pancreatitis. Right-upper-abdominal pain, fever, jaundice, or dark urine can be gallbladder warning signs and should not be managed through self-directed tablet changes.
- In adult weight-reduction trials, gallstones were reported with both Wegovy tablets and injection; the current label reports cholelithiasis in 2.5% of tablet-treated participants versus 1% on tablet placebo.
- Inability to keep fluids down, very low urine output, fainting, confusion, or worsening weakness needs prompt assessment rather than generic hydration advice alone.
- A clinician may need to assess hydration, kidney function, gallbladder symptoms, pancreatitis, another diagnosis, and whether treatment should be paused or changed.
Thyroid, glucose, eye, allergy, and heart review
Medical history and other medicines can change the safety plan
Wegovy carries a boxed warning about thyroid C-cell tumors and is contraindicated with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. The label also warns about low blood sugar, especially when semaglutide is used with insulin or a sulfonylurea; serious allergic reactions; diabetic-retinopathy complications in at-risk patients; and increased heart rate. Patients should not stop insulin, reduce a sulfonylurea, or use a universal pulse threshold without the clinicians managing those medicines.
- Report a neck mass, persistent hoarseness, trouble swallowing, or breathing difficulty to a clinician; the warning does not mean every patient will develop thyroid cancer.
- Severe low-blood-sugar symptoms, fainting, sudden vision changes, facial or throat swelling, or breathing trouble need urgent evaluation.
- Review diabetes medicines, eye history, kidney history, diuretics, blood-pressure medicines, stimulants, prior GLP-1 reactions, and current heart-rate symptoms before treatment changes.
Pregnancy, procedures, and oral medicines
A daily pill still requires pregnancy, anesthesia, and medication-timing review
Wegovy should not be used for weight loss during pregnancy, and the label directs patients planning pregnancy to stop semaglutide in advance under prescriber guidance. Semaglutide also delays gastric emptying, which can affect absorption of oral medicines and is relevant before procedures using general anesthesia or deep sedation because rare pulmonary-aspiration events have been reported with GLP-1 receptor agonists. The labeled tablet routine requires an empty stomach and spacing from food, beverages, and other oral medicines, but patients should not invent a timing workaround or procedure hold schedule.
- Discuss pregnancy plans, possible pregnancy, breastfeeding, contraception, and all oral medicines before starting or continuing Wegovy tablets.
- Tell the surgeon, proceduralist, anesthesia team, and Wegovy prescriber before a planned procedure, then follow their individualized instructions.
- Ask the prescriber or pharmacist how delayed stomach emptying and the morning tablet routine apply to medicines with narrow therapeutic windows or strict timing requirements.
Product and seller verification
Oral Wegovy is legitimate; “generic Wegovy pills” and no-prescription offers are not the labeled product
The current Wegovy label includes branded once-daily semaglutide tablets, so oral Wegovy is no longer automatically a counterfeit claim. That does not validate every website, social post, imported product, loose tablet, supplement patch, research chemical, or purported compounded semaglutide pill. A legitimate pathway should identify the exact branded product, licensed prescriber, dispensing pharmacy, labeled packaging, total cost, side-effect contact, and follow-up plan. Compounded medications, when clinically and legally appropriate for an individualized need, are not FDA-approved finished drug products and should not be marketed as generic Wegovy.
- Avoid no-prescription checkout, hidden pharmacy sourcing, non-labeled strengths, loose tablets, crypto-only payment, copied escalation charts, or guaranteed weight-loss claims.
- Avoid sellers claiming the tablet has no side effects, works despite ignoring label timing, or can be stacked with Wegovy injection, Ozempic, Rybelsus, tirzepatide, Foundayo, or another GLP-1 medicine.
- Verify product identity before using side-effect information; Rybelsus and Foundayo are different oral GLP-1 products with different labels.